TNF and myeloid sarcoma: Although the increased production of TNF-α with a clinically effective treatment appears to be counterintuitive, the beneficial role of TNF-α in MS is substantiated by clinical trials showing that anti–TNF-α treatment in patients leads to significant worsening of disease activity (57).